Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma
- 10 July 2004
- journal article
- clinical trial
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 54 (5), 385-390
- https://doi.org/10.1007/s00280-004-0837-7
Abstract
The outcome of systemic chemotherapy in metastatic hepatocellular carcinoma (HCC) patients had been disappointing. Based on the demonstrated antitumor activities and different mechanisms of action and toxicity profiles, we designed a phase II trial of combination therapy with doxorubicin and cisplatin in metastatic HCC patients anticipating a synergistic interaction of the combination.Keywords
This publication has 18 references indexed in Scilit:
- Treatment of hepatocellular carcinoma (HCC) with systemic chemotherapy combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF regimen)Cancer Chemotherapy and Pharmacology, 2002
- Annual Report of the Korea Central Cancer Registry Program 2000: Based on Registered Data from 131 HospitalsCancer Research and Treatment, 2002
- Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon‐alpha, doxorubicin and 5‐fluorouracil chemotherapyCancer, 2002
- Natural History of Untreated Nonsurgical Hepatocellular Carcinoma: Rationale for the Design and Evaluation of Therapeutic TrialsHepatology, 1999
- Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumoursEuropean Journal Of Cancer, 1995
- Hepatic Resection for Hepatocellular Carcinoma An Audit of 343 PatientsAnnals of Surgery, 1995
- MDR1 (multidrug resistance) gene expression in human primary liver cancer and cirrhosisJournal of Hepatology, 1993
- Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trialCancer, 1988
- A random phase II study of mitoxantrone and cisplatin in patients with hepatocellular carcinoma: An ECOG studyCancer, 1987
- Primary hepatocellular cancer—present results and future prospectsInternational Journal of Radiation Oncology*Biology*Physics, 1983